Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease: Survival Estimates From the EMPA-REG OUTCOME Trial

被引：32
|
作者：
Claggett, Brian [1 ]
Lachin, John M. [2 ]
Hantel, Stefan [3 ]
Fitchett, David [4 ,5 ]
Inzucchi, Silvio E. [6 ]
Woerle, Hans J. [7 ]
George, Jyothis T. [7 ]
Zinman, Bernard [5 ,8 ]
机构：
[1] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
[2] George Washington Univ, Biostat Ctr, Rockville, MD USA
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[4] St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Yale Univ, Endocrinol Sect, Sch Med, New Haven, CT USA
[7] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[8] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
CIRCULATION | 2018年 / 138卷 / 15期
关键词：
cardiovascular diseases; diabetes mellitus; empagliflozin;
D O I：
10.1161/CIRCULATIONAHA.118.033810
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1599 / 1601
页数：3
相关论文
共 50 条
  • [31] Effects of empagliflozin on cardiorenal outcomes in patients with type 2 diabetes and proteinuric diabetic kidney disease: insights from EMPA-REG OUTCOME
    Wanner, Christoph
    Zinman, Bernard
    von Eynatten, Maximilian
    Koitka-Weber, Audrey
    Zwiener, Isabella
    Hauske, Sibylle J.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
  • [32] Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial
    Pellicori, Pierpaolo
    Fitchett, David
    Kosiborod, Mikhail N.
    Ofstad, Anne P.
    Seman, Leo
    Zinman, Bernard
    Zwiener, Isabella
    Wanner, Christoph
    George, Jyothis
    Inzucchi, Silvio E.
    Testani, Jeffrey M.
    Cleland, John G. F.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (07) : 1085 - 1093
  • [33] Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial
    Hadjadj, Samy
    Cooper, Mark E.
    Steubl, Dominik
    Petrini, Michaela
    Hantel, Stefan
    Mattheus, Michaela
    Wanner, Christoph
    Thomas, Merlin C.
    KIDNEY MEDICINE, 2024, 6 (03)
  • [34] Effect of empagliflozin on anthropometry and indices of visceral and total adiposity in patients with type 2 diabetes and high cardiovascular risk: EMPA-REG OUTCOME
    Neeland, L. J.
    McGuire, D. K.
    Fernandez, C. S.
    Mattheus, M.
    Woerle, H. -J.
    Johansen, O.
    Fitchett, D.
    DIABETOLOGIA, 2016, 59 : S348 - S348
  • [35] Effect of empagliflozin when added to insulin in patients with type 2 diabetes and high cardiovascular (CV) risk: results from EMPA-REG OUTCOME
    Jurisic-Erzen, D.
    Johansen, O.
    George, J.
    Mattheus, M.
    Zinman, B.
    Inzucchi, S.
    DIABETOLOGIA, 2016, 59 : S349 - S349
  • [36] Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG
    Ryden, Lars
    Shahim, Bahira
    Mellbin, Linda
    CLINICAL THERAPEUTICS, 2016, 38 (06) : 1279 - 1287
  • [37] A phase III trial of empagliflozin in patients with Type 2 diabetes with stage 2 or 3 chronic kidney disease (EMPA-REG RENAL™)
    Barnett, A. H.
    Mithal, A.
    Manassie, J.
    Jones, R.
    Rattunde, H.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2014, 31 : 63 - 63
  • [38] Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD): post hoc analyses of the EMPA-REG OUTCOME trial
    Ferreira, J. P.
    Verma, S.
    David, F.
    Ofstad, A. P.
    Lauer, S.
    Zwiener, I.
    George, J. T.
    Wanner, C.
    Zinman, B.
    Inzucchi, S. E.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S450 - S451
  • [39] EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL
    Ruggenenti, Piero
    Inzucchi, Silvio
    Zinman, Bernard
    Hantel, Stefan
    Koitka-Weber, Audrey
    von Eynatten, Maximilian
    Wanner, Christoph
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 : 487 - 487
  • [40] Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial
    Sharma, Abhinav
    Ofstad, Anne Pernille
    Ahmad, Tariq
    Zinman, Bernard
    Zwiener, Isabella
    Fitchett, David H.
    Wanner, Christoph
    George, Jyothis T.
    Hantel, Stefan
    Desai, Nihar
    Mentz, Robert J.
    DIABETES, 2020, 69
12345